- Biotech on the Web - https://biotechontheweb.com -

Regeneron drug reduces bone growth for patients with ultra-rare skeletal disease

Share:
[1] [2] [3] [4]

Patients with the ultra-rare disease FOP grow bone where it doesn’t belong, creating a life-threatening second skeleton. Regeneron Pharmaceuticals believes it can offer hope: A new treatment reduced new bone growth by 90% in a clinical trial, the company said, a result that could lead to Food and Drug Administration approval.

More at:  https://www.statnews.com/2020/01/09/regeneron-drug-reduces-bone-growth-rare-skeletal-disease/ [5]

Author: Editorial Team [6]